id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15251 R62715 |
Dudukina (Controls exposed to LTG) (Mixed indications), 2023 | Hyperkinetic disorders including Attention deficit hyperactivity disorder (ADHD) | 3 months (or more) before pregnancy or during pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes |
1.08 [0.78;1.47] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15252 R62736 |
Dudukina (Controls unexposed, NOS) (Mixed indications), 2023 | Hyperkinetic disorders including Attention deficit hyperactivity disorder (ADHD) | 3 months (or more) before pregnancy or during pregnancy excluded | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes |
1.41 [1.11;1.80] excluded (exposition period) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 0 studies | NaN [NaN;NaN] | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |